Actively Recruiting
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-05-13
110
Participants Needed
7
Research Sites
147 weeks
Total Duration
On this page
Sponsors
N
Nanjing Leads Biolabs Co.,Ltd
Lead Sponsor
P
Peking University Cancer Hospital & Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
CONDITIONS
Official Title
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Agree to follow the trial treatment plan, visit schedule, laboratory tests, and other protocol requirements, and voluntarily sign informed consent.
- Age 18 years or older at the time of signing informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Expected survival time of at least 12 weeks.
- At least one measurable lesion according to RECIST 1.1 criteria.
- Adequate organ and bone marrow function as shown by laboratory tests.
- Males able to father children and females of childbearing age agree to use effective contraception from consent signing until 6 months after last trial drug dose; females must have a negative pregnancy test within 7 days before first dose.
You will not qualify if you...
- Participation in other antineoplastic clinical studies within 4 weeks before first study drug dose or planned anti-tumor therapy outside this study during the trial.
- Use of immunomodulatory drugs within 2 weeks before first study drug dose.
- Active or recurrent autoimmune diseases.
- Clinically uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage or intervention.
- History of immunodeficiency including HIV positive.
- Active hepatitis B or C infection.
- Pregnancy or breastfeeding.
- Any other condition deemed by the investigator to affect compliance or suitability for participation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
2
AnYang Tumor Hospital
Anyang, Henan, China, 455000
Not Yet Recruiting
3
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China, 471003
Actively Recruiting
4
Henan Cancer Hospital
Zhengzhou, Henan, China, 450000
Actively Recruiting
5
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 451191
Actively Recruiting
6
Shandong Cancer Hospital
Jinan, Shandong, China, 250117
Actively Recruiting
7
Suining Central Hospital
Suining, Sichuan, China, 629099
Actively Recruiting
Research Team
L
Lin Shen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here